ASML Holding vs Roche: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: ASML Holding and Roche side by side

1. 1896Roche

   F. Hoffmann-La Roche Founded in Basel

   Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.

2. 1898Roche

   Commercial Breakthrough with Sirolin

   Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.

3. 1934Roche

   First Industrial Synthesis of Vitamin C

   Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.

4. 1963Roche

   Launch of Valium (Diazepam)

   Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.

5. 1968Roche

   Establishment of Roche Diagnostics

   Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.

6. 1984ASML Holding

   Founded as ASM Lithography in Eindhoven

   ASM Lithography starts operations on April 1, 1984 as a joint venture between Philips and ASM International, with the mandate to commercialize the PAS 2000 wafer stepper developed inside Philips.

7. 1986ASML Holding

   PAS 2500 stepper and the Carl Zeiss partnership

   ASML brings the PAS 2500 stepper to market with a new wafer alignment system developed by first chief scientist Steef Wittekoek, and establishes the optics partnership with Carl Zeiss that still supplies every ASML lithography system.

8. 1988ASML Holding

   ASM International withdraws and Philips funds a rescue

   With few customers and heavy cash consumption, ASM International decides to stop funding the joint venture while Philips launches a company-wide cost-cutting program.

9. 1991ASML Holding

   PAS 5500 platform turns the company around

   ASML launches the PAS 5500 platform, whose productivity and resolution win the first large orders from Intel and IBM under chief executive Willem Maris and take the company to profitability. PAS 5500 systems are still running in customer fabs decades later.

10. 1995ASML Holding

    IPO in Amsterdam and on Nasdaq

    ASML becomes a fully independent public company with a dual listing on the Amsterdam Stock Exchange and Nasdaq. Philips sells half of its shares at the IPO and divests the remainder over the following years.

11. 2001ASML Holding

    TWINSCAN platform launched and Silicon Valley Group acquired

    ASML introduces the TWINSCAN dual-stage architecture, which exposes one wafer while the next is measured and aligned, lifting throughput and overlay accuracy above competing systems.

12. 2003ASML Holding

    First immersion lithography system

    The TWINSCAN AT:1150i debuts as ASML's first immersion machine, projecting 193 nanometer light through a layer of ultrapure water between the lens and the wafer to raise resolution.

13. 2008Roche

    Severin Schwan becomes CEO

    Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.

14. 2009Roche

    Full Acquisition of Genentech for $46.8 Billion

    Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.

15. 2010ASML Holding

    First EUV prototype shipped

    ASML ships the TWINSCAN NXE:3100, its first extreme ultraviolet lithography tool, to the research facility of an Asian chipmaker.

16. 2012ASML Holding

    Customer Co-Investment Program with Intel, TSMC and Samsung

    Intel, TSMC and Samsung acquire newly issued ASML shares equal to an aggregate 23 percent minority stake for ~$4.35 billion (3.85 billion euros) in cash, and separately commit ~$1.56 billion (1.38 billion euros) of R&D funding over five years dedicated to EUV…

17. 2013ASML Holding

    Cymer acquisition completed and second-generation EUV shipped

    ASML completes the acquisition of Cymer, the San Diego supplier of the light sources used in its lithography systems, in a cash-and-stock deal valued at ~$2.2 billion (1.95 billion euros) when it was agreed in October 2012.

18. 2017ASML Holding

    EUV enters high-volume manufacturing

    ASML begins shipping the production-ready TWINSCAN NXE:3400B after customers started ordering the NXE:3400 generation in batches in 2016, roughly two decades after EUV research began.

19. 2018Roche

    Foundation Medicine & Flatiron Health Acquisitions

    Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.

20. 2019ASML Holding

    Dutch government stops EUV exports to China

    The Netherlands does not renew ASML's export licence for EUV systems to China, the start of a widening export control regime.

21. 2023ASML Holding

    First High-NA EUV system shipped

    ASML ships the first of its next-generation EUV systems with a numerical aperture of 0.55, the TWINSCAN EXE:5000, to Intel in Hillsboro, Oregon.

22. 2023Roche

    Acquired Telavant

    F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.

23. 2024ASML Holding

    Christophe Fouquet becomes chief executive

    Peter Wennink and Martin van den Brink step down as presidents of ASML on April 24, 2024 and Christophe Fouquet becomes president, chief executive officer and chair of the Board of Management.

24. 2025ASML Holding

    Record year, first EXE:5200B and Mistral AI investment

    ASML reports total net sales of ~$37 billion (32.7 billion euros), up 15.6 percent, net income of ~$10.8 billion (9.6 billion euros), a gross margin of 52.8 percent and 535 systems sold, and closes the year with a backlog of ~$43.8 billion (38.8 billion euros)…

25. 2025Roche

    Group Sales Reach CHF 61.5 Billion

    Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.

Acquisitions

Questions about ASML Holding vs Roche